Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Abbott has received approval from the U.S. Food and Drug Administration (FDA) for its TriClip transcatheter edge-to-edge repair (TEER) system designed to treat tricuspid regurgitation (TR).

FDA approves Abbott’s TriClip TEER device for tricuspid regurgitation

Less than two months after an FDA advisory panel voted in favor of approval, the transcatheter edge-to-edge repair system can now be sold and marketed in the United States.

Newsweek ranked the 50 best heart hospitals in the world

Moderate prosthesis-patient mismatch after SAVR linked to worse long-term outcomes

The long-term impact of moderate PPM remains unclear. To learn more, researchers explored dozens of different studies from over the years, sharing their work in the Journal of the American Heart Association.

New risk score helps cardiologists predict when TAVR patients may require dialysis

Patients who need renal replacement therapy after TAVR are much less likely to survive. Researchers hope their new risk score can help care teams prepare ahead of time for this rare, but potentially fatal complication. 

Medtronic has received U.S. Food and Drug Administration (FDA) approval for its Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.

FDA approves Medtronic’s next-generation TAVR system with new frame design

The Evolut FX+ TAVR system includes an updated diamond-shaped frame, which was made four times larger than previous models to offer improved coronary access. It was also designed to provide more space for operators to guide and maneuver the catheter during procedures.

Heart attacks after TAVR: New AMI data ‘reassuring’ at first glance, but questions remain

Hoping to gain a better understanding of how TAVR may impact a patient’s long-term cardiovascular health, researchers explored data from more than 200,000 patients and shared their findings in JACC: Cardiovascular Interventions.

doctor comparing the costs of different medical treatments

TAVR is often more cost-effective than SAVR—but not always

Average lengths of stay and common complications are just some of the factors care teams should consider when evaluating the costs of aortic valve replacement. 

Virtual reality (VR) can help cardiologists plan for transcatheter aortic valve replacement (TAVR) procedures and predict the presence and severity of post-TAVR paravalvular leak (PVL), according to new research published in the Journal of Invasive Cardiology.[1]

VR before TAVR predicts paravalvular leak in high-risk patients

Performing virtual reality simulations before TAVR may help cardiologists anticipate when PVL could be an issue in patients with severe BAV AS.

Hoping to improve care for these patients, Hermann et al. turned to the ŌNŌ retrieval system, a catheter-delivered device cleared by the U.S. Food and Drug Administration in 2022. The device was developed by Ōnōcor, a U.S. healthcare startup with roots in the Penn Center for Innovation.

Cardiologists are first in world to remove unstable Watchman devices with FDA-cleared retrieval system

A team of specialists in Houston made history, using the new-look device to treat three patients over the age of 80. The group shared its experience in JACC: Clinical Electrophysiology.

Displaying 249 - 256 of 981
Design by Adaptive Theme